Following the issuance of Globavir's press release announcing the companies intention to develop its lead drug candidate, GBV006, for the treatment of Ebola, Shalabh Gupta (President & CEO) was interviewed by Sasha Damouni of Bloomberg First Word. Bloomberg First Word is news wire service used by investment analysts to quickly obtain relevant and summarized news content on companies.
The following is an excerpt of the content issued:
"Globavir Biosciences is in informal discussions with WHO, Medecins Sans Frontieres regarding development of Ebola drug candidate GBV006, CEO Shalabh Gupta said in interview with Bloomberg First Word.
Within a few weeks, animal studies should be complete. As soon as data are released, Globavir will look for government, NGO partners to distribute in future.
Given side-effect profile human trials could happen before the end of the year.
Unlike any other biopharma co., Globavir is using a combination of existing approved drugs, which don't have supply issues seen with monoclonal antibodies. Tekmira Pharma, Mapp Biopharmaceutical are currently out of supply with their treatments, have little S-T visibility of when products will be ready for distribution, he said.
NOTE: On Aug. 13, TKMR said it will take months to boost Ebola drug. Mapp's drug supply has already been exhausted
Firm's such as NewLink, GlaxoSmithKline are exploring vaccines for Ebola which may take several months before becoming available, he said.
NOTE: Aug. 14 story, First Use of Ebola Vaccine Appear at Least a Month Away Vaccines take longer, because you are giving it to someone and relying on an immunological response, Gupta said.
Discovery of the use of GBV006 for the treatment of infectious diseases was made at Stanford University School of Medicine."